Company intelligence / Profile preview
Amytrx Therapeutics
Nashville, Tennessee, United Statesamytrx.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
Amytrx’s lead candidate AMTX-100 has completed a Phase I trial in atopic dermatitis showing that about half of patients achieved total or near-total clearance of lesions after one week of treatment. The improvement continued post-treatment. The company has initiated a Phase IIb trial to further assess safety and efficacy in mild to moderate atopic dermatitis. Preclinical studies support potential expansion into multiple inflammatory and autoimmune diseases
- Therapeutic areas
- Infectious DiseasesDermatologyGastroenterologyEndocrinologyImmunologyCardiovascular
- Modalities
- Peptide therapeutics (specifically synthetic peptides)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Amarex Clinical Research (for clinical trial design and management)open to collaborations but no major pharma partnerships disclosed as of now
Beyond the preview
Go deeper on Amytrx Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amytrx Therapeutics.